1 published article · Updated continuously
18 trials tracked for Angina pectoris: 5 in phase 3 or 4 and 1 with published results. The most-cited published study has 118 citations.
Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Ranolazine reduced average weekly angina frequency (5.2 vs 4.5, p=0.008) and average weekly sublingual nitroglycerin use (3.6 vs 2.9, p=0.003) over the last 6 weeks of treatment in a phase 4 trial of 949 patients 1. The percentage of weeks with at least a 50% reduction in angina frequency was 41% vs 46% 1. In a separate phase 3 trial of 2651 patients, ranolazine did not significantly affect time to first ischemia-driven revascularization or hospitalization (p=0.48), sudden cardiac death (p=0.40), or cardiovascular death (p=0.82) 4.
Caduet (amlodipine/atorvastatin) produced percent changes from baseline in LDL-C ranging from -10.9 to -7.4 to -10.5 to -12.3 to -12.2 across visits, total cholesterol from -7.3 to -5.0 to -7.9 to -8.0 to -8.1, and HDL-C from 1.5 to 4.0 to -0.5 to 2.2 to 2.5 in a phase 4 trial of 159 patients 3.
The Orsiro DES was associated with target lesion failure at 12 months in 9% of participants (p<0.0001) in a trial of 556 patients 10. In another trial of 1334 patients, Bayesian estimated target lesion failure at 12 months was 6.32% vs 8.90%, with device success in 1082 vs 566 lesions (p=0.415) 11.
Near infrared spectroscopy imaging resulted in zero clinical cardiac events definitely attributable to the study device from enrollment to 7 days post enrollment in a phase 3 trial of 106 patients 5. Succinate metoprolol was studied in a phase 4 trial of 251 patients, but no outcome results were reported 2.
AI synthesis of 12 cited trials, updated Sep 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
